Tracker · Last reviewed Oct 9, 2026
Pipeline Map
Tracked mental-health programs in development, organized by how they work, how far they have come, and what changed.
Programs
27
29 tracks
Advanced · 90D
1
Moved up a stage
Setbacks
1
Misses, holds, CRLs
Discontinued
2
Currently discontinued
Catalysts · 6 MO
8
Through Apr 11, 2027
Movement tracking since Oct 9, 2026. 90-day history covers 3 of 29 tracks shown; the rest are not counted as steady, because their history is not yet recorded.
| Pharma2 tracksAxsome Therapeutics · AXSM | Agitation associated with dementia due to Alzheimer's disease | NMDA modulatorDrug | Approved | No change | Apr 30, 2026 | — |
|---|---|---|---|---|---|---|
| Pharma2 tracksAxsome Therapeutics · AXSM | Major depressive disorder | NMDA modulatorDrug | Approved | No 90-day history | May 9, 2026 | — |
| PharmaOtsuka | ADHD (adults and children 6+, at least 20 kg) | Monoamine reuptake inhibitorDrug | Approved | No 90-day history | Jul 24, 2026 | — |
| PharmaBristol Myers Squibb | Schizophrenia | Muscarinic M1/M4Drug | Approved | No 90-day history | May 15, 2026 | — |
| DigitalClick Therapeutics | Negative symptoms of schizophrenia (adults 18+); adjunct to outpatient care | Neuromodulation & digitalDevice / digital | AuthorizedFDA 510(k)-cleared | ▲ from Submitted | Jul 30, 2026 | — |
| PharmaJohnson & Johnson · JNJ | Treatment-resistant depression | NMDA modulatorDrug | Approved | No 90-day history | Feb 27, 2026 | — |
| DigitalOtsuka / Click Therapeutics | Major depressive disorder (adjunct) | Neuromodulation & digitalDevice / digital | AuthorizedFDA 510(k)-cleared | No 90-day history | Apr 4, 2026 | — |
| DigitalBig Health | Chronic insomnia (adults 18+) and generalized anxiety disorder (adults 22+); adjunct to usual care | Neuromodulation & digitalDevice / digital | AuthorizedFDA 510(k)-cleared | No 90-day history | Jan 12, 2026 | — |
| PharmaSupernus (Biogen collaboration) · SUPN | Postpartum depression | GABA-A modulatorDrug | Approved | No 90-day history | Apr 18, 2026 | — |
| PsychedelicsEli Lilly (formerly AtaiBeckley) · LLY | Treatment-resistant depression | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Sep 11, 2026 | — |
| PharmaEli Lilly · LLY | Major depressive disorder; alcohol use disorder | GIP / GLP-1 agonistDrug | Phase 3 | No 90-day history | Feb 10, 2026 | — |
| PsychedelicsCompass Pathways · CMPS | Treatment-resistant depression | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Aug 5, 2026 | Q4 2026NDA submission guided to complete in Q4 2026 |
| Psychedelics2 tracksDefinium Therapeutics (formerly MindMed) · DFTX | Generalized anxiety disorder | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Sep 14, 2026 | H1 2027NDA submission guided for the first half of 2027 |
| Psychedelics2 tracksDefinium Therapeutics (formerly MindMed) · DFTX | Major depressive disorder | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Sep 8, 2026 | 2027Ascend Phase 3 topline results guided for 2027 |
| PharmaVistagen Therapeutics | Social anxiety disorder (acute treatment) | Nasal chemosensoryDrug | Phase 3 | No 90-day history | Sep 22, 2026 | — |
| PsychedelicsHelus Pharma (formerly Cybin) · HELP | Major depressive disorder | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Jul 21, 2026 | Q4 2026APPROACH Phase 3 topline results guided for Q4 2026 |
| PsychedelicsResilient Pharmaceuticals (formerly Lykos) | PTSD | EntactogenDrug + therapy | Phase 3 | No 90-day history | Jun 6, 2025 | — |
| PharmaNeumora Therapeutics | Major depressive disorder | κ-opioid antagonistDrug | Phase 3 | × Discontinued | Jun 15, 2026 | — |
| PharmaNeurocrine Biosciences · NBIX | Schizophrenia | Muscarinic M1/M4Drug | Phase 3 | No 90-day history | Dec 24, 2025 | 2027Phase 3 data in schizophrenia guided for 2027 |
| PharmaAcadia Pharmaceuticals · ACAD | Alzheimer's disease psychosis | 5-HT2A antagonistDrug | Phase 3 | ‖ Setback | Sep 24, 2026 | — |
| PharmaJohnson & Johnson · JNJ | Major depressive disorder with insomnia symptoms | Orexin antagonistDrug | Phase 3 | No 90-day history | Sep 22, 2025 | — |
| PsychedelicsTranscend Therapeutics (Otsuka subsidiary since June 2026) | PTSD | EntactogenDrug | Phase 3 | No 90-day history | Jun 12, 2026 | — |
| PsychedelicsUsona Institute | Major depressive disorder | Serotonergic psychedelicDrug | Phase 3 | No 90-day history | Jan 5, 2026 | — |
| CannabisHarmony Biosciences | Fragile X syndrome | CannabinoidDrug | Phase 3 | × Discontinued | Feb 24, 2026 | — |
| PharmaAbbVie (Cerevel) · ABBV | Schizophrenia | Muscarinic M1/M4Drug | Phase 2 | No 90-day history | Jan 22, 2026 | — |
| PsychedelicsGH Research · GHRS | Treatment-resistant depression | Serotonergic psychedelicDrug | Phase 2 | No 90-day history | Aug 6, 2026 | 2026Pivotal program initiation guided for 2026 |
| PsychedelicsHelus Pharma (formerly Cybin) · HELP | Generalized anxiety disorder | Serotonergic psychedelicDrug | Phase 2 | No 90-day history | Mar 5, 2026 | — |
| PsychedelicsReunion Neuroscience | Postpartum depression | Serotonergic psychedelicDrug | Phase 2 | No 90-day history | Feb 23, 2026 | 2026Pivotal Phase 3 start guided for 2026 |
| PsychedelicsEli Lilly (formerly AtaiBeckley) · LLY | Treatment-resistant depression | Serotonergic psychedelicDrug | Phase 2 | No 90-day history | Aug 11, 2026 | Q4 2026Elumina Phase 2b topline results guided for Q4 2026 |
Last reviewed Oct 9, 2026. Each row carries its own verification date, shown in the program detail.